Clinical Insights Into the Biology and Treatment of Pancreatic Cancer.
Repository Usage Stats
Pancreatic cancer is a devastating disease with a universally poor prognosis. In 2015, it is estimated that there will be 48,960 new cases of pancreatic cancer and that 40,560 people will die of the disease. The 5-year survival rate is 7.2% for all patients with pancreatic cancer; however, survival depends greatly on the stage at diagnosis. Unfortunately, 53% of patients already have metastatic disease at diagnosis, which corresponds to a 5-year survival rate of 2.4%. Even for the 9% of patients with localized disease confined to the pancreas, the 5-year survival is still modest at only 27.1%. These grim statistics highlight the need for ways to identify cohorts of individuals at highest risk, methods to screen those at highest risk to identify preinvasive pathologic precursors, and development of effective systemic therapies. Recent clinical and translational progress has emphasized the relationship with diabetes, the role of the stroma, and the interplay of each of these with inflammation in the pathobiology of pancreatic cancer. In this article, we will discuss these relationships and how they might translate into novel management strategies for the treatment of this disease.
SubjectCell Transformation, Neoplastic
Combined Modality Therapy
Published Version (Please cite this version)10.1200/JOP.2015.009092
Publication InfoMettu, Niharika B; & Abbruzzese, James L (2016). Clinical Insights Into the Biology and Treatment of Pancreatic Cancer. J Oncol Pract, 12(1). pp. 17-23. 10.1200/JOP.2015.009092. Retrieved from https://hdl.handle.net/10161/11572.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
More InfoShow full item record
D. C. I. Distinguished Professor of Medical Oncology
My research interests include the clinical study and treatment of pancreatic cancer.
Assistant Professor of Medicine
My long-term goal is to develop new therapies to treat patients with gastrointestinal and other solid tumors. To accomplish this, I am active in designing, writing, and running phase I and II clinical trials. I am also interested in the correlative science that furthers our understanding of cancer at a molecular level. I am interested in the identification of biomarkers, which are characteristics of a given patient's tumor that may help us to understand his or her prognosis or how well he or she
Alphabetical list of authors with Scholars@Duke profiles.